Marano P, Patti F, Nicoletti F
Institute of Neurologic Clinics, Catania University, Sicily.
Curr Med Res Opin. 1988;11(1):41-4. doi: 10.1185/03007998809111129.
A double-blind, parallel group study was carried out in 50 patients with an anxiety disorder to compare the anxiolytic efficacy and tolerability of a recently developed benzodiazepine, metaclazepam, with that of bromazepam. Patients were allocated at random to receive treatment for 2 weeks with either 15 mg metaclazepam or 4 mg bromazepam per day in two divided doses. Assessments were made using the Hamilton anxiety rating scale (physician) on entry and after 7 and 13-days' treatment, and a visual analogue scale (patients) on entry and at the end of the study. The results showed that there was a significant, marked reduction in anxiety rating scores after 1 and 2 weeks in both groups and a significant improvement in the patients' subjective assessment of their condition after treatment. Few side-effects were reported in either group.
一项双盲平行组研究在50名焦虑症患者中进行，以比较一种新开发的苯二氮䓬类药物美他西泮与溴西泮的抗焦虑疗效和耐受性。患者被随机分配，接受为期2周的治疗，每天服用15毫克美他西泮或4毫克溴西泮，分两次服用。在入组时、治疗7天和13天后，使用汉密尔顿焦虑评定量表（由医生评定）进行评估；在入组时和研究结束时，使用视觉模拟量表（由患者评定）进行评估。结果显示，两组在治疗1周和2周后焦虑评定分数均有显著、明显的降低，且患者对自身状况的主观评估在治疗后有显著改善。两组报告的副作用均较少。
